You are here: Home » Markets » News
Business Standard

Dr Reddy's Laboratories gains as Q2 profit beat estimates

The stock was up 3% at Rs 4,336, extending its previous day's 2.6% gain on the NSE.

SI Reporter  |  Mumbai 

Dr Reddy's Laboratories gains as Q2 profit beat estimates

Dr Reddy’s Laboratories is trading higher by 3% at Rs 4,336, extending its previous day’s 2.6% gain on the NSE, in otherwise subdued market after the drug maker reported a better-than expected 46% year on year (YoY) growth in net profit at Rs 721 crore for the second quarter ended September 30, 2015 (Q2). It had profit of Rs 574 crore in a year ago quarter.

Net income from sales and services during the quarter grew 11% YoY at Rs 3,989 crore mainly driven by global generics.

In global generics, the key markets- USA, Europe and India, posted a growth of 32%, 65% and 14% yoy, Dr Reddy’s Laboratories said in a statement.

Revenues from Emerging however declined by 22% YoY, it added.

Analysts on an average had expected profit of Rs 650 crore and net sales of Rs 3,964 crore for the quarter.

Earnings before interest, tax, depreciation and amortization (EBITDA) margin improved 430 basis points to 28.6% from 24.3%.

The stock hit an intra-day high of Rs 4,365, is less than 1% away from its record high of Rs 4,387 on NSE touched in last week on October 20. Till 09:57 am, a combined 416,537 shares changed hands on the counter on the NSE and BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, October 30 2015. 09:59 IST